Literature DB >> 11379848

Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.

J E Grant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11379848     DOI： 10.4088/jcp.v62n0413e

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  5 in total

1.  Olanzapine augmentation of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

Review 2.  Recognizing and treating body dysmorphic disorder.

Authors:  Jon E Grant; Katharine A Phillips
Journal:  Ann Clin Psychiatry       Date:  2005 Oct-Dec       Impact factor: 1.567

Review 3.  Body dysmorphic disorder.

Authors:  Andri S Bjornsson; Elizabeth R Didie; Katharine A Phillips
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

4.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18

Review 5.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.